NY-PHILIP-MORRIS-INTL
19.9.2023 14:34:29 CEST | Business Wire | Press release
A potential tenfold reduction in smoking-attributable deaths is possible if people who currently smoke were to switch to smoke-free products, Jacek Olczak, CEO of Philip Morris International Inc. (PMI) (NYSE: PM) will state in a speech today. He will explain the role smoke-free products can play in ending cigarette smoking globally and the human consequences of inaction.
“For over a decade, PMI has championed a smoke-free future. Having invested more than $10.5 billion to scientifically research, develop, and commercialize smoke-free products—which today account for more than a third of our total net revenues—we are living this future,” says Olczak. “Yet, inexplicably, there are countries stuck in the past where smokers can easily access cigarettes—the most harmful form of nicotine consumption—but not the better option of smoke-free alternatives.”
Using the World Health Organization’s data, estimates, and methodologies, along with other third-party data, PMI calculated the potential public health impact of the world’s smokers switching from cigarettes to less harmful, smoke-free products. The hypothetical model shows that if smoke-free products are assumed to be 80 percent less risky than cigarettes and if people who currently smoke were to switch to them completely, then over their lifetime, there’s a potential for a tenfold reduction in smoking-attributable deaths compared with historical tobacco control measures alone.
In a world that demands change, people are counting on their governments to keep up with technological advancements while ensuring innovations are appropriately regulated. According to a new international survey conducted by independent research firm Povaddo for PMI, more than half of global respondents (56 percent) believe their government needs to consider the role better alternatives such as e-cigarettes and heated tobacco products can play in eradicating cigarette use in their country.
Moreover, 8 in 10 global respondents (82 percent) agree they would be somewhat or very angry, frustrated, or upset to learn that a breakthrough that could help address a societal issue was not made available to the public due to government inaction, and 88 percent agree that public health authorities should fully embrace and seek to learn from evidence and data from other countries.
During a streamed broadcast via Reuters’ (@ReutersPlus) on X (formerly Twitter) today at 10am ET, Olczak explains that, while there are limitations to any hypothetical analysis, real-world examples from countries that accept tobacco harm reduction confirm its positive impact.
Public health data show1, for instance, that Sweden has one of the lowest smoking rates in the developed world, at just 5.8 percent. This is largely due to the availability of snus—a moist oral tobacco product—which Swedish men began switching to decades ago. Today, male mortality rates due to tobacco are much lower in Sweden2 compared with other European Union countries, where snus is banned. Putting that in perspective, the Swedish Snus Commission estimates that more than 350,000 smoking-attributable deaths among men could have been avoided each year if the other EU countries had matched Sweden’s tobacco-related mortality rate.
There is also compelling evidence from Japan. In 2019—five years after heated tobacco products were introduced in that country—independent studies3 showed an unprecedented decline in cigarette sales. The U.K., which has adopted smoke-free products to help adults abandon cigarettes, has also seen smoking rates fall significantly.4
“Innovations become advancements when they address existing issues and offer improvements. Decades ago, our industry was challenged to make cigarettes less harmful. We have delivered, creating science-based alternatives that remove combustion, the primary factor in smoking-related disease,” says Olczak. “It is no longer a case of if smoke-free alternatives are better than cigarette smoking; it is a case of by how much.”
A video of Olczak’s full speech will be accessible here from 10am ET and additional information on PMI’s hypothetical model is available at pmi.com/rethinkdisruption.
Survey Methodology
Povaddo conducted the online survey on behalf of PMI between March 30 and April 20, 2023. The survey was fielded among 30,591 general population adults aged 21 or older in 15 countries: Argentina, Austria, Brazil, Colombia, Dominican Republic, Malaysia, Mexico, Pakistan, Philippines, Serbia, South Africa, South Korea, Tunisia, United Kingdom, and United States. Approximately 2,000 interviews were collected in each country. Data have been weighted by age, gender, and nicotine product use per market to match national statistics. Results are accurate to a margin of error of +/- 1 percent.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’ IQOS and ZYN brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI’s IQOS Platform 1 devices and consumables and Swedish Match’s General Snus as Modified Risk Tobacco Products (MRTPs). As of June 30, 2023, PMI’s smoke-free products were available for sale in 80 markets, and PMI estimates that approximately 19.4 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 35.4 percent of PMI’s total second-quarter 2023 net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com and www.pmiscience.com.
# # #
1 Swedish National Public Health Survey
3 National Health and Nutrition Survey, Japan
4 Smoking Habits in the UK and Constituent Countries, 2021 dataset edition
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919717263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
